SCM
RCUS icon

Sterling Capital Management’s Arcus Biosciences RCUS Stock Holding History

Sterling Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.5K Sell
1,135
-440
-28% -$9.5K ﹤0.01% 1934
2025
Q4 		$37.5K Buy
1,575
+196
+14% +$4K ﹤0.01% 1915
2025
Q3 		$18.8K Buy
1,379
+761
+123% +$7.91K ﹤0.01% 2175
2025
Q2 		$5.03K Buy
618
+562
+1,004% +$4.8K ﹤0.01% 2513
2025
Q1 		$440 Hold
56
– – ﹤0.01% 2980
2024
Q4 		$834 Hold
56
– – ﹤0.01% 2977
2024
Q3 		$856 Buy
+56
New +$883 ﹤0.01% 2616

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sterling Capital Management's RCUS Position: Q1 2026 in Review

Sterling Capital Management reduced its Arcus Biosciences (RCUS) stake by 28% in Q1 2026, selling an estimated $9.5K and leaving 1,135 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1934.

Sterling Capital Management first reported a position in RCUS in Q3 2024 and has held it in 7 quarters since. The position peaked at $37.5K in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Sterling Capital Management held 1,135 shares of Arcus Biosciences worth $24.5K as of Q1 2026.
  • Sterling Capital Management sold 440 Arcus Biosciences shares in Q1 2026, an estimated $9.5K.
  • Arcus Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1934 holding.
  • Sterling Capital Management first reported a position in Arcus Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Arcus Biosciences position peaked at $37.5K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.